Chong-Hui Gu, PhD, is responsible for CMC, supply chain and quality assurance at Foghorn Therapeutics. He brings 20 years of drug discovery and development experiences in multiple disease areas.
Prior to joining Foghorn, Chong-Hui was VP, CMC and DHODH program leader at Agios Pharmaceuticals, where he led the CMC development of IDHIFA®, TIBSOVO®, mitapivat and vorasidenib. Prior to that, he held positions at Vertex Pharmaceuticals and Bristol-Myers Squibb, where he contributed to the formulation and CMC development of INCIVEK®, KALYDECO®, ORKAMBI® and ELIQUIS®.
Chong-Hui received a PhD in pharmaceutics from the University of Minnesota, Twin Cities, and a BS in pharmacy from Fudan University in China.